FDA Clarifies Use of Product Names in Advertising and Promotional Labeling


The U.S. Food and Drug Administration recently published final guidance to clarify the requirements for the use of product names in promotional labeling and advertising for prescription drugs (including biological drug products).  This newsletter provides a brief summary of the guidance and its implications.

On January 24, 2012, the U.S. Food and Drug Administration (FDA) posted final guidance entitled Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling.  The final guidance, which modifies a draft guidance issued in January 1999, is intended to clarify the agency’s interpretation of the requirements for product name placement, size, prominence and frequency in promotional labeling and advertising for prescription human drugs (including biological drug products) and prescription animal drugs.  The recommendations provided in the final guidance apply to the use of product names in traditional print media, audio-visual (AV) promotional labeling (e.g., videos shown in a doctor’s office), broadcast media advertisements and electronic media (e.g., internet, social media, e-mail).  The guidance discusses requirements relating to single active ingredient products and products with two or more active ingredients.

The following topics are addressed in the sections of the final guidance that pertain to products with one active ingredient...

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Antitrust & Trade Regulation Updates, Communications & Media Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »